Cencora, Inc. $COR Position Trimmed by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. lowered its stake in Cencora, Inc. (NYSE:COR) by 21.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 70,646 shares of the company’s stock after selling 19,436 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Cencora were worth $21,183,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of COR. Atlantic Edge Private Wealth Management LLC boosted its position in shares of Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares during the period. Obermeyer Wealth Partners lifted its stake in Cencora by 1.3% during the first quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company’s stock valued at $758,000 after buying an additional 36 shares in the last quarter. Grove Bank & Trust boosted its holdings in shares of Cencora by 4.3% in the second quarter. Grove Bank & Trust now owns 879 shares of the company’s stock worth $264,000 after buying an additional 36 shares during the period. U.S. Capital Wealth Advisors LLC increased its position in shares of Cencora by 0.4% in the second quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock worth $2,563,000 after acquiring an additional 38 shares in the last quarter. Finally, Monument Capital Management raised its holdings in shares of Cencora by 2.4% during the second quarter. Monument Capital Management now owns 1,637 shares of the company’s stock valued at $491,000 after acquiring an additional 38 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the sale, the chief executive officer owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. The trade was a 11.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 41,544 shares of company stock valued at $12,230,941 over the last quarter. Corporate insiders own 10.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on COR shares. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Cencora in a research note on Thursday, October 30th. Evercore ISI set a $400.00 target price on Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. Mizuho lifted their price target on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. JPMorgan Chase & Co. increased their price objective on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Finally, Wells Fargo & Company lifted their target price on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, Cencora presently has an average rating of “Moderate Buy” and a consensus target price of $371.09.

Cencora Price Performance

COR opened at $361.80 on Wednesday. The stock has a fifty day moving average price of $323.97 and a 200 day moving average price of $303.25. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $369.00. The stock has a market cap of $70.14 billion, a price-to-earnings ratio of 37.22, a PEG ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. The company had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business’s revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, November 14th. This is a boost from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s payout ratio is 30.19%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.